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Abstract: Growing evidence suggests the causal link between the endocrine-disrupting chemicals
(EDCs) and the global obesity epidemics, in the context in the so-called “obesogenic environment”.
Dietary intake of contaminated foods and water, especially in association with unhealthy eating
pattern, and inhalation of airborne pollutants represent the major sources of human exposure to EDCs.
This is of particular concern in view of the potential impact of obesity on chronic non-transmissible
diseases, such as type 2 diabetes, cardiovascular disease, and hormone-sensitive cancers. The key
concept is the identification of adipose tissue not only as a preferential site of storage of EDCs,
but also as an endocrine organ and, as such, susceptible to endocrine disruption. The timing of
exposure to EDCs is critical to the outcome of that exposure, with early lifetime exposures (e.g., fetal
or early postnatal) particularly detrimental because of their permanent effects on obesity later in life.
Despite that the mechanisms operating in EDCs effects might vary enormously, this minireview is
aimed to provide a general overview on the possible association between the pandemics of obesity
and EDCs, briefly describing the endocrine mechanisms linking EDCs exposure and latent onset
of obesity.
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1. Introduction
Global obesity epidemics is most likely due to the interactions among heterogeneous
causes, that include dysregulation of endocrine and metabolic systems, genetic predisposition,
and environmental factors, in the context of the so-called “obesogenic environment” [1].
Although it has been estimated that the heritability of obesity range goes from 30% to 70%,
the relative weight of genetic factors and environmental influences might be difficult to disentangle [2].
Epigenetics is a potential link between environmental exposures and gene activity, and both
obligatory and facilitated epigenetic variations could account for the missing heritability of obesity [3].
Novel molecular approaches evaluating the phenotypic discordance in monozygotic twins, such as
genome-wide methylation assays, point out that epigenetic changes induced by lifestyle are likely
operating distinctly for each individual in the pathogenesis of obesity and related comorbidities [4].
Among the “obesogenic” environmental factors, a growing body of evidence supports that
the exposure to certain environmental pollutants can contribute to the pandemics of obesity also
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independently of unhealthy diet and physical inactivity [5], especially in wealthy industrialized
countries and in urban settings with elevated concentrations of primary air pollutants [6]. This is of
particular concern in view of the potential impact of obesity on chronic non-transmissible diseases,
such as type 2 diabetes, cardiovascular disease, and hormone-sensitive cancers. In both animal models
and humans, the majority of environmental pollutants work by perturbing the endocrine systems and
altering hormone action as endocrine-disrupting chemicals (EDCs) [5,7]. Increasing knowledge on
the causal link between health effects and EDCs represents a great challenge for health care systems
considering that, according to currently available literature, the socio-economic burden of EDC-related
diseases for the countries of the Eurozone ranges between 46 and 288 billion €/year [8].
The aim of this minireview is to provide a general overview on the possible association
between the pandemics of obesity and most common environmental pollutants acting as EDCs,
briefly describing the endocrine mechanisms linking EDCs exposure and latent onset of obesity.
2. Endocrine-Disrupting Chemicals (EDCs)
EDCs are described as “exogenous chemicals or mixtures of chemicals that alter function(s) of the
endocrine system and consequently cause adverse health effects in an intact organism, or its progeny,
or (sub)populations” (World Health Organization, WHO). EDCs are ubiquitous in the environment,
including atmosphere, sediments, soils, water, and are derived both from industrial chemicals,
such as bisphenol A and phthalates used as plastic packaging components and other consumer
products, from agricultural sources, such as pesticides, fungicides, insecticides, or herbicides, or can
occur naturally, such as phytoestrogens. Human pollutant exposure is predominantly through the
consumption of contaminated tap water and food, mainly meat, fish, and dairy products, especially in
association with unhealthy eating pattern, or by dermal exposure due to direct contact of the skin with
the EDCs or from the ambient air, and by inhalation of volatile contaminants and airborne fine and
ultrafine particulate matter (PM) often generated through widely-used thermal processes, such as the
combustion of fuels or the thermal decomposition of waste [9].
Based on the World Health Organization/International Programme on Chemical Safety 2002
definition of EDCs [9], the vast majority of the POPs currently listed in the Stockholm Convention
are EDCs (i.e., those chemicals that have potential to interact with the hormone systems, but the
adversity of such interaction is yet to be studied or recognized). As many EDCs are lipid soluble,
they easily accumulate in human tissues throughout a life span, mainly in adipose tissue and in
overweight/obese populations [9]. EDCs can interfere with the endocrine system at multiple levels,
by influencing hormone synthesis, release, transport, metabolism and excretion [7]. In particular,
EDCs act by agonizing or antagonizing the effects of hormones through mechanisms dependent or
independent of nuclear receptors, resulting in the transcription of target genes involved in homeostasis
and developmental processes. A major issue in the study of EDCs is the apparent complexity of
their mechanisms of action, which may occur through multiple signaling pathways and targets.
In addition, the exposure to different levels of EDCs produces diverse phenotypes, thereby resulting in
nonmonotonic dose-response curves [10]. Notably, the complexity is further increased as animals and
humans are exposed to complex mixtures of EDCs instead of single compounds. Thus, the mechanisms
operating in EDCs effects might vary enormously.
Adverse effects of about 800 chemicals with EDCs properties that are used in daily life have been
shown in both humans and wildlife [9]. The endocrine disrupting effects in relation to different systems,
organs and sources of exposure have been examined in a recent review, including both experimental
and epidemiological data [11]. A key role for EDCs has been proposed in the pathogenesis of early
puberty, infertility, altered quality of sperm, and reproductive disorders later in life in both animal
and human studies [11]. Altered thyroid and adrenal hormones biosynthesis and functions have been
also included among commonly occurring EDCs adverse effects [11]. In addition, a growing body of
evidence indicates a pivotal role for EDCs in promoting the obesity epidemics [12].
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3. “Obesogenic” EDCs from the Endocrinologic Point of View
The global increase in the production of EDCs parallels the worldwide increase in obesity
prevalence, lending support to the “obesogen” hypothesis [7]. A role for EDCs in the etiology of
obesity was initially postulated in the early 2000s when Baillie-Hamilton reported that the global
obesity epidemic coincided with the marked increase of industrial chemicals in the environment over
the past 40 years [13]. Since the Baille-Hamilton review, an increasing number of experimental and
clinical studies support the key role for exposure to EDCs in the obesity epidemics [14–16]. The term
“obesogens” was coined by Grun and Blumberg as “xenobiotic chemicals that can disrupt the normal
developmental and homeostatic controls over adipogenesis and/or energy balance” [17]. According
to the “obesogen hypothesis”, the prenatal or early-life exposure to certain EDCs predisposes some
individuals to gain excessive adipose tissue [7]. The key concept is the identification of adipose
tissue not only as a preferential site of storage of EDCs, but also as an endocrine organ and, as such,
susceptible to endocrine disruption, especially in critical windows of development, such as pre and
early postnatal life, or puberty. Of interest, while the weight gain in adults is predominantly due to
changes in size of pre-existing adipocytes in most adipose depots, the increased adipogenesis during
early development permanently establishes an elevated adipocyte number in adulthood. The inability
of adipose tissue to further expand in order to tackle the chronic positive balance between food energy
intake and expenditure, is responsible for the development of a dysfunctional adipose tissue that
contributes to obesity and obesity-associated metabolic complications [18].
In general, the environmental exposure to specific EDCs, identified as “obesogenic and/or
diabetogenic”, induces obesity by disrupting the homeostatic control of adipogenesis and/or energy
balance [19]. There are multiple mechanisms involved in EDC-induced obesity. “Obesogenic”
EDCs interfere with different endocrine-regulated metabolic processes, including lipid and glucose
metabolism and insulin signaling pathway [11,20]. In addition, “obesogenic” EDCs promote
adipogenesis in cellular models, promote either adipogenesis and obesity in animal models as well
as in humans [5], and influence the neuroendocrine control of appetite and satiety in experimental
animals [9]. Furthermore, EDCs interfere with pro-inflammatory mechanisms by activating oxidative
stress-sensitive transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B
cells (NFκB), and inducing cytokines, chemokines, and adhesion molecules in the vascular endothelium.
Low grade chronic inflammation can be considered a strong basis for the metabolic alterations of obesity
epidemics, such as visceral adiposity and insulin resistance [21]. Through these pro-inflammatory
mechanisms, EDCs are correlated with an increased risk of non-communicable or chronic diseases, such
as atherosclerosis, type 2 diabetes, obesity, nonalcoholic fatty liver (NAFLD), the hepatic expression of
the metabolic syndrome, cardiovascular disease, and hormone-sensitive cancers later in life [11,22–24].
In this, EDCs could represent a model of the interaction between environmental and genetic factors
involved in the development of obesity/diabetes/metabolic syndrome, although the metabolic
consequences might vary with gender, and dose and time of EDCs exposure [5]. Of interest, the
adipose tissue expansion might play a dual role of promoting metabolic disorders and type 2 diabetes
on the one side, but providing a relatively safe place to store EDCs on the other side.
Epigenetic variations and shift in gut microbiota profile are sensible targets for EDCs “obesogen”
effects. Possible mechanisms by which early life EDC exposure can affect epigenetic programming
of obesity are binding, activation or inhibition of nuclear receptors and other transcription factors
that regulate the expression of the target genes [25]. The timing of exposure to EDCs is critical to the
outcome of that exposure, with early lifetime exposures (e.g., fetal or early postnatal) particularly
detrimental because of their permanent effects [21]. Data on both animal and human data clearly
indicates that exposure to “obesogenic” EDCs during critical periods in the early life, such as during
organogenesis and around puberty, induces epigenetic, transgenerational modifications, i.e., heritable
changes of gene expression without accompanying changes in the DNA sequence manifested across
multiple generations [26]. The epigenetic, transgenerational modifications induced by EDCs include
expression of noncoding RNAs, alterations in chromatin structure, and transcriptional activity resulting
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from changes in DNA and histone methylation. Low levels of DNA methylation at gene promoters
might generate active adipogenic genes, thereby permanently increasing adipocyte number and
favoring central fat deposition in the presence of energy imbalance. The hyperactivity of adipogenic
genes fosters to create an altered metabolic set point, thereby influencing latent effects on the risk
of obesity and obesity-related outcomes, and likely accounting also for the very common issue of
weight regain after weight loss [27]. Of interest, novel molecular approaches evaluating the phenotypic
discordance in monozygotic twins, such as genome-wide methylation assays, point out that epigenetic
changes induced by lifestyle are likely operating distinctly during adolescence/adult life for each
individual in the pathogenesis of obesity and related comorbidities [4]. Accordingly, maternal weight
loss is associated with changes in gene methylation/expression of different inflammatory pathways in
the offspring and reduced inflammatory marker levels [28].
The most common epigenetic variations in obesity in humans have been evaluated by a recent
meta-analysis [29]. In particular, EDCs act as ligands for the Peroxisome Proliferator-Activated
Receptors-γ (PPARγ) and their binding is associated with DNA methylation variation of PPARγ or
PPARγ target genes. PPARγ is a pivotal molecule in the regulation of adipogenesis highly expressed in
adipose tissue, where it regulates not only the differentiation into adipocytes, but also the accumulation
of triglycerides, glucose metabolism, and insulin sensitivity in mature adipocytes [30–32]. “Obesogenic”
EDCs can potentially promote adipose tissue accrual during early development preferentially
committing the mesenchymal stem cells toward differentiation into adipocytes in a process dependent
by binding to PPARγ, with regulation of the relative expression of PPARγ-induced genes. As the vast
majority of EDCs are lipophilic, it therefore flows that these compounds might easily accumulate in
the adipose tissue over the years. Thus, a continuous spiral is created, with the increased burden of
EDCs stored in the body fat along with the EDC-induced accrual of adipose tissue [19] (Figure 1).
Further DNA methylation variations associated with exposure to EDCs occur in the promoter of the
retinoid X receptor α gene (RXRα), a nuclear receptor reported to explain up to 26% of the variation
in childhood adiposity. RXRα exerts a pivotal role in adipogenesis by forming a heterodimer with
PPARγ, and in PPARγ coactivator-1 (PGC-1), a tissue-specific transcriptional coactivator associated
with weight loss, obesity, and risk for type 2 diabetes mellitus [29]. In addition to binding to PPARγ,
EDCs promote preadipocyte differentiation through different regulatory pathways, including the
agonistic effects on estrogen (ER), glucocorticoid, and aryl-hydrocarbon receptors (AhR) [7]. Other
possible mechanisms of EDCs action evidenced in experimental models include: direct effects on
insulin signaling with decreased expression of insulin-dependent genes involved in lipid homeostasis
in pre-adipocyte 3T3-L1cell line, activation of genes related to the inflammatory pathway in human
adipocytes likely through the AhR, increased mRNA expression, as well as the enzymatic activity of
11β-hydroxysteroid dehydrogenase type 1, known to induce adipogenesis in humans by converting
cortisone to cortisol in adipose tissue.
Both the host gastrointestinal tract and the commensal gut microbiota are likely to be exposed to
and modulated by EDCs through the diet. A number of studies suggest that the interactions between
gut microbiota and environmental toxicants may contribute in part to the development of obesity and
diabetes [33,34]. In particular, the AhR, a receptor highly expressed by intestinal intraepithelial
lymphocytes and actively controlling immune homeostasis in the gut, is bound and activated
by a variety of polychlorinated biphenyls (PCBs). Recent evidence indicates that gut microbiota,
which can be modulated by the AhR [35], may play a pivotal role in the “obesogen” effects of these
compounds. In animal experimental studies, EDCs, in particular 2,3,7,8 tetrachlorodibenzofuran,
alter the composition of the gut microbiota after its binding to the AhR [34]. Changes in gut microbiota
profile are associated with the alteration of their inherent metabolic activity, with significantly increased
levels of bile acids and short-chain fatty acids, altered liver function, increased intestinal inflammation,
and inhibited signaling of the farnesoid X receptor, a key regulator of fat and glucose metabolism [36].
Below it is provided a more detailed description concerning the EDCs more commonly associated
with obesity.
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preferentially committing the mesenchymal stem cells toward differentiation into adipocytes regulating
the relative expression of PPARγ-induced genes. As the vast majority of EDCs are lipo hilic, these
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4. Diethylstilbestrol
Diethylstilbestrol (DES) is a non-steroidal estrogen that was initially used to prevent adverse
pregnancy outcomes from the late 1940s to 1971 and commonly used as a growth promoter in animal
production [37]. The mechanism of DES toxicity includes its interference with the reproductive
system and association with fem l reproductive tr ct cancers, in both exposed women and heir
offsprings [38].
Animal studies sugge ted that, although multiple pathways might e involved in the
programming for obesity, DES exposure during prenatal or perinatal period was linked to weight and
body fat ncrea e, p rsi tin in a ulthood [39]. It was hy othesized that DES exposure works o the
genetic programming of adypocit s and on their distribution by interac ing with ER nd different g nes
and transcript onal factors, including gene implicated in altered adipocyte differentiation and function
(Hoxa5, Gpc4, and Tbx15), as well as fat cell distribution (Thbd, Nr2f1, a d Sfrp2) [40]. In addition, high
levels of markers of adiposity, such as leptin, and proinflammatory cytokines, such as interleukin 6
(IL-6), were f und in mice models in the early phase of exposur , suggesting that these could constitute
e rly markers for the evelopment of metabolic syndrome and obesity r lated diseases later in life.
Alterations in glucose metabolism along ith a high prevalence f pancreatic β-cell yp rplasia we
also found in DES exposed mice [39]. Dat fro the National Canc r Institute DES Follow up Study
on prenatally DES-exposed wom n supported the association betwe n DES and adult obesity in
humans [37]. In particular, the adjusted risk ratio for DES and obesity among 2871 prenatally exposed
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compared to 1352 unexposed women aged 23–52 years at baseline in 1994 was 1.09 (CI: 0.97–1.22), thus
suggesting that prenatal DES exposure might be associated with a small increase in adult obesity.
5. Bisphenol A
Bisphenol-A (BPA), a component of polycarbonate plastics and resins, is one of the highest-volume
chemicals produced worldwide. BPA has largely been found in the production of food and beverages
into which BPA leaches from polycarbonate containers, including reusable bottles baby bottles, toys.
However, BPA is also commonly found in thermal paper and also dental composites. Human BPA
exposure can occur through ingestion, inhalation, or dermal absorption from contaminated materials.
Foods and water can be contaminated by BPA monomers as a result of the heating or either acidic
or basic conditions during storage. BPA has been detected in 93% of urine samples of the general
population in the United States [24]. Due to its nearly ubiquitous environmental contamination, BPA
concentration in human serum ranges from 0.2 to 1.6 ng/mL [25], but BPA has been found also in
amniotic fluid, neonatal blood, placenta, cord blood, and human breast milk [41–43].
It is known that BPA is a ER panagonist, and the interaction with ERs influences the expression of
estrogen-responsive genes [44–46], interfering with reproductive function [47,48]. In addition to its
well documented actions on the reproductive system, BPA exerts a wide variety of metabolic effects.
Although the pancreatic islets and adipocytes are not considered classical targets of estrogen, both
express functional ERs [49]. Consequently, BPA exposure has been demonstrated to have a key role in
the pathogenesis of multiple metabolic disorders, promoting insulin resistance, disruption of pancreatic
β-cell function, hepatotoxicity, and obesity [50]. Data from the 2003/04 and 2005/06 National Health
and Nutrition Examination Surveys (NHANES) evidenced that urinary BPA concentration in adult
population was positively associated with general and central obesity, especially in men [51].
BPA is a lipophilic molecule that accumulates in adipose tissue, where interferes in the mechanisms
of adipose tissue differentiation. in vitro experiments revealed that in both 3T3-L1 cells and human
adipose stromal/stem cells the presence of BPA promoted an increase in triglyceride content and
adipogenesis, inhibited the adiponectin release [50], and increased the release of proinflammatory
cytokines, such as IL-6 and IFN-γ, by activation of JNK, STAT3 and NFkB pathways [52], while in a
hepatoma cell line it increased triglyceride content and lipid accumulation along with the decrease in
expression of some genes involved in lipid oxidation [53]. More recently, in 3T3-L1 pre-adipocytes BPA
increased the expression of PPAR-γ, Fatty Acid Binding Protein 4/Adipocyte Protein 2 (FABP4/AP2)
and CCAAT/enhancer binding protein (C/EBPα), while in mature adipocytes BPA increased lipid
accumulation and reduced insulin-stimulated glucose utilization [54]. The adipogenic effect of BPA has
been proposed to be mediated by an ER-dependent mechanism, along with the enhanced expression of
DLK (leucine zipper-bearing kinase), insulin-like growth factor-1 (IGF-1), C/EBPα, or PPARγ among
other factors [14,55]. Furthermore, BPA has been reported to promote the adipogenesis by increasing
expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 [56], the thyroid
receptor/retinoic X receptor or mammalian target of rapamycin signaling pathways [57]. Previous
in vivo studies have demonstrated that the prenatal BPA exposure is linked to DNA methylation
variation of Insulin-like Growth Factor 2 (IGF-2) and H19, two reciprocally expressed imprinted genes
located on chromosome 11p15.5 that play a major role in fetal and placental growth [29].
Finally, low grade chronic inflammation and adipocyte dysfunction have been also proposed
as the causal link between BPA and obesity in different clinical settings, including subjects with
visceral obesity [58] and women with polycystic ovary syndrome (PCOS) [59]. The possible
relationships between BPA and PCOS pathogenesis, involving in utero exposure to BPA, liver-spleen
axis, hyperandrogenism, and low-grade inflammation, are depicted in Figure 2. In particular,
besides a direct hepatotoxic and adipogenetic effect [50], BPA could act as pro-inflammatory primer,
via macrophage activation and pro-inflammatory cytokine hypersecretion, with a possible link with
immune/autoimmune derangement in women with PCOS. PCOS exposure to low-chronic BPA
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doses might initiate or exacerbates obesity and insulin resistance, while in turn, BPA influences
androgen metabolism.
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Figure 2. A possible pathway involving BPA, liver-spleen axis, hyperandrogenism, and low-grade
inflammation in pathogenesis of the polycystic ovary syndrome taking into account the suggested
role of BPA as EDC for the “environmental obesogen hypothesis”, and considering the possible
relationship between in utero exposure to BPA and PCOS pathogenesis. Besides a direct hepatotoxic
and adipogenetic effect, BPA could act as pro-inflammatory primer, via macrophage activation and
pro-inflammatory cytokine hypersecretion, being spleen enlargement as marker of this process, with
a possible link with immune/autoimmune derangement in women with PCOS. PCOS exposure to
low-chronic BPA doses might initiate or exacerbates obesity and IR, while in turn, BPA influences
androgen metabolism. BPA, Bisphenol A; EDCs, endocrine-disrupting chemicals; PCOS, polycystic
ovary syndrome; IR, insulin resistance.
6. Phytoestrogens
Phytoestrogens are naturally-occurring plant compounds found in a wide variety of foods, most
notably soy, and commonly known as “dietary estrogens”. Indeed, exposure to phytoestrogens
is mainly due to the increased consumption of soy products and soy supplements in the effort
to implement healthier eating lifestyles. Soy proteins are used as a meat substitute in hotdogs,
hamburgers, sausages and other meat products or are widely available as dietary supplements to
enrich energy bars, sports drinks, infant formulas, cereals, imitation dairy products, and ice cream.
The health benefits frequently attributed to phytoestrogens include a lowered risk of osteoporosis,
heart disease, lipid disorders, breast cancer, and menopausal symptoms [60]. However, because of their
chemical analogy with 17-β-estradiol, phytoestrogens are able to induce estrogenic or anti-estrogenic
effects, interacting with ERs. Therefore, phytoestrogens are also considered EDCs, indicating that they
have the potential to cause adverse health effects as well [61]. Besides their primary role as EDCs on
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reproductive outcomes, phytoestrogens are also supposed to interact with the normal adipose tissue
regulation and proliferation, mainly in the early period of development. Genistein, the predominant
isoflavone in soybean, has been proposed as a promising compound for the treatment of metabolic
disorders due to its anti-oxidant and anti-inflammatory effects [60]. However, at the low dosage
commonly found in Western and Eastern diet, genistein seems to be responsible of changes in the
expression of metabolic and adipogenic regulators, such as PPAR-γ and others, thus promoting
fat accumulation in adipose tissue, especially in males [62]. Recent experimental data supported
that genistein dysregulates the body composition, in a dose-dependent and gender-specific manner,
disrupting and reprogramming the signals dictating adipose tissue expansion, likely throughout the
early-life epigenetic regulation of Wnt10b, a further key adipogenic gene in adipose tissue [15].
7. Phthalates
Phthalates are diesters of phthalic acid and are used in the production of plastics to improve the
quality of these products, such as polyvinyl chloride (PVC), and are also commonly found in many
consumer products, such as food and beverage packaging, soaps, shampoos, cosmetics, and hairsprays.
Phthalates are released into the environment from PVC and plastic materials, so human exposure can
easily occur through dermal absorption from contaminated materials or inhalation or ingestion [63].
In particular, children can be easily exposed to the effects of phthalates released in food or beverages
containers, plastic toys or other plastics.
Researches in mice models show that phthalates metabolites could be responsible for increasing
adipogenesis and insulin resistance by activating PPAR-γ receptors expression in the period of
adipocytes differentiation [64]. Among results of human studies investigating the effects of phthalate
exposure on obesity, data from the National Health and Nutrition Examination Survey (NHANES)
1999–2002 evidenced a positive association between urinary excretion of phthalates metabolites and
waist circumference in both male and female adults was found [65], while more recent studies from
NHANES 2007–2010 found that phthalates were associated with higher odds for obesity in both adults
and children of both gender [66].
A further potential mechanism linking phthalates to obesity might be provided by the
anti-androgenic effects of these compounds. Of interest, testosterone is a key hormone in the pathology
of metabolic diseases and obesity, and a low androgenic activity has been related with the development
of overweight and obesity [67]. The anti-androgenic effects might be mediated via the inhibition of
Leydig cell steroidogenesis at different ages of fetal development [68] or by indirectly interacting with
the normal activity of androgen receptors, via the PPAR-α expressed in gonads [69].
8. Organochlorine and Organophosphate Pesticides
In the general population, the dietary intake of pesticides is the most important source of EDC
exposure [70]. Organochlorine pesticides (OCPs) are chlorinated hydrocarbons used from the 1940s
through the 1960s and then banned in the United States and many other countries according to
the Stockholm Convention on Persistent Organic Pollutants in 2001. Unfortunately, some of these
compounds are still registered for use and are detected in tap water, posing a serious risk to worldwide
human health and the environment. Organophoshates (OPPs), esters of phosphoric acid, have
often been selected to replace persistent OCPs and represent up to 50% of all the insecticide use
worldwide [70]. The accidental inhalation or ingestion of these compounds in fish, dairy products, and
other fatty foods that are contaminated, represent the most common way of human exposure. After
entering into the food chain, these compounds tend to persist in the environment and accumulate in
fat mass of mammals due to their high lipophilicity, causing disrupting effects on endocrine, immune,
and reproductive systems [20].
Exposure to OCPs has been linked to metabolic disorders, such as obesity and type 2 diabetes.
Inflammation, as a known mechanism accompanying insulin resistance, has also been shown to arise
in insulin target tissues exposed to OCPs. In recent studies, selected OCPs are recognized to predict
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insulin resistance, higher body weight and altered lipidic profile in exposed populations [71]. Several
hypotheses to explain how these chemicals could give metabolic dysregulation have been analyzed,
including interference on PPARγ expression, production of inflammatory cytokines, such as Tumor
Necrosis Factor-α (TNF-α), and alterations in steroid metabolism with anti-androgenic effect [72].
Very recently, OCPs such as p,p1-dichlorodiphenyldichloroethylene (DDE), have been indicated as
responsible of enhancing adipogenesis and intracellular lipid accumulation in 3T3-L1 cells through
up-regulation of molecular targets responsible for lipid storage, including fatty acid binding protein 4
and Sterol regulatory element-binding protein-1c [73].
A strict link has been reported between the early-life OPPs exposure and the subsequent
emergence of hyperinsulinemia and hyperlipidemia, depicting an overall pattern essentially
resembling prediabetes, through the pathway synthesizing cyclic AMP controlled by adenylyl cyclase,
the common site for disruption by OPPs [70]. In addition, recent evidence indicated that dietary
chronic exposure to chlorpyrifos, the most used OPPs worldwide, increased food intake and promotes
weight gain in mice with Apolipoprotein E3 isoform, the most common in humans, unraveling relevant
interactions between toxic exposure to chlorpyrifos and genetic predisposition [74].
9. Polychlorinated Bisphenols
PCBs are a class of organic chemicals widely used, mainly in electrical equipment. Although
PCBs were banned at the end of the 1970s in many countries because of environmental toxicity,
these compounds still remain present in the environment due to their high stability and represent
one of the key constituents of POPs all over the world [75]. On the basis of their biochemical
properties, some PCBs are classified as dioxin-like compounds and exert many effects after their
the binding to the AhR. In addition to their neurotoxicity, some PCBs are identified as EDCs because
of their estrogenic and antiandrogenic effects [76] and interference with thyroid metabolism [77].
As documented by prospective epidemiologic studies, PCBs act as “obesogens” when exposure occurs
in fetal period, during the phases of adypocites differentiation [78,79]. PBCs exposure is associated
with the development of the metabolic syndrome and childhood obesity, with a clear gender difference
as the associations were stronger in girls compared to boys [80].
10. Perfluoroalkyl Substances
Perfluoroalkyl substances (PFASs) are ubiquitous non-organochlorine POPs, widely used in
industrial applications and detectable in the blood of human populations worldwide. Similarly
to other POPs, they are able to persist in the environment, and to accumulate in human tissues,
with adverse effects on exposed individuals [81]. The contamination can occur through the contact
of food, drinking water, or inhaling dust [82]. Some recent researches reported on the association
between PFASs exposure in prenatal life and the development of overweight in childhood [83,84].
Different targets were identified for different groups of PFASs. Indeed, PFAS are known to activate
PPARα, a receptor involved in regulating gene expression related to lipid and glucose metabolism,
but PPARα-dependent or independent mechanisms vary widely across PFASs [85]. In particular,
plasma concentrations of PFASs were positively associated with both total and HDL cholesterol in
pregnant women, where higher total cholesterol is associated with elevated risk of preeclampsia [86].
11. Inhaled Pollutants
In 2004, the first American Heart Association scientific statement on “Air Pollution and
Cardiovascular Disease” concluded that exposure to PM air pollution contributes to cardiovascular
morbidity and mortality [87]. The association between obesity and the cardiovascular health effects
of fine particulate air pollution (PM2.5) has been extensively evaluated by a meta-analysis including
three large prospective cohort studies and 14 panel studies with short-term follow-up [88]. Results
of this meta-analysis suggested that obesity may modify the impact of PM2.5 on cardiovascular
health, as obese people may be more susceptible to the cardiovascular health effects of ambient
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PM2.5, with a higher risk of cardiovascular mortality among obese subjects also after adjusting for
a number of potential confounding factors. Endothelial dysfunction and reactive oxygen species
generation via activation of alveolar macrophage and systemic vascular oxidases including the
NAD(P)H, mitochondrial and xanthine oxidases, appear to mediate this risk [89]. In addition,
PM2.5 exposure enhances the expression of proinflammatory cytokines, such as IL-6 and TNF-α [90].
Thus, mechanistically, inhaled pollution particles induce a local inflammatory response in the lung
that is initiated by alveolar macrophages and airway epithelial cells. Subsequently, these systemic
mediators translocate from the lung into the circulation eliciting the classic systemic inflammatory
response, with production of acute phase proteins by the liver. The increase in circulating leukocytes,
platelets, and proinflammatory/prothrombotic proteins could constitute the link for the development
of obesity, insulin resistance, endothelial dysfunction and progression of atherosclerosis induced by
PM2.5 exposure [91]. Accordingly, recent studies evaluated a role for environmental exposition to
PM2.5 in the development of metabolic abnormalities typical of obesity, type 2 diabetes and metabolic
syndrome in both animal models and in humans. In high-fat diet-fed rats, inhaled pollutants increased
insulin resistance, visceral fat, and systemic and cellular inflammatory markers [16]. In humans, there
is a strong association between long-term air pollution exposure and various components of metabolic
syndrome, with subsequent cardio-metabolic effects [92,93].
Further mechanisms have been described for the association between of inhaled pollutants and
obesity. Environmental pollutants resulting from incomplete combustion, such as polycyclic aromatic
hydrocarbons (PAHs) and including benzo[a]pyrene, are characterized by the capacity to bind to
DNA, forming PAH–DNA adducts. Thus, besides their well known carcinogenic effects, PAHs might
act as “obesogens” by altered methylation of PPARγ or PPARγ target genes. Furthermore, although
limited data exists on the potential role of inhaled pollutants on liver disease in the general population,
PM2.5 has the potential to induce Kupffer cell cytokine secretion by the liver, thus representing
a significant risk factor for NAFLD progression [94]. In addition, Thomson and colleagues [95]
have recently reported that inhalation of particulate matter or ozone increases plasma levels of the
hypothalamic-pituitary-adrenal (HPA) axis stress hormones in rats to limit the inflammatory signaling
in the lungs. The chronic stimulation of glucocorticoids induces well-characterized effects on both
peripheral metabolism and food intake [96]. On the one hand, glucocorticoids up-regulate glucagon
and inhibit insulin action, resulting in increased gluconeogenesis, impaired peripheral glucose uptake,
and disruption of insulin receptor signaling [97]. On the other hand, glucocorticoids stimulate visceral
fat accumulation, protein breakdown, and eating behavior by facilitating orexigenic activity of NPY
and AgRP neurons [98]. In addition, during and after exposure to acute or chronic stress, the activation
of HPA axis inhibits a number of endocrine axes, including somatotropic, thyrotropic and gonadal
axes, which are all known to exert relevant effects on body composition and weight gain [99,100].
In this context, it is tempting to speculate that activation of HPA axis as response to the systemic
inflammation induced by inhaled pollutants might elicit similar complex endocrine perturbations.
Thus, the persistent dysregulation of HPA axis might lead to the amplification of detrimental effects
on body composition, thereby potentially affecting the susceptibility to obesity and non-transmissible
chronic diseases during lifespan.
12. Conclusions
The data included in this brief review support a mechanistic endocrine link between the early
environmental exposure to EDCs and the development of obesity and of obesity-related diseases later
in life.
The adipocytes are endocrine cells producing and receiving endocrine signals from different
endocrine tissues and, as such, susceptible to EDCs, especially in critical windows of development.
“Obesogen” actions of EDCs should be considered parts of a very complex scenario resulting from
multiple and bidirectional relationships between EDCs and genetic, epigenetic and environmental
factors, including parental diet/exposure, lifestyle, dietary habits, gut microbiota. In addition, it should
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be considered that the “obesogen” mechanisms operating early in life might vary enormously later in
life due the chronic exposure to EDCs throughout the entire life span of the exposed individuals.
The wide range of different EDC classes and modality of exposure, the need of highly selective and
sensitive analytical methods for the measurement of EDCs and the evaluation of the biological effects in
humans and wildlife tissues, and the relative scarcity of information on socio-economic cost estimates,
make it challenging to adopt primary preventive measures for dealing with the “obesogen” effects
linked to the environmental exposure to EDCs. Nevertheless, as growing evidence indicates that the
exposure to EDCs might account for a relevant part of the incidence of obesity and related-conditions,
then stronger controls on EDCs could generate better health and significant financial savings each year
for health care services [101].
Additional studies including prospective intervention trials in controlled populations, especially
considering the important confounding effect of diet, are mandatory to determine the relevance of
some hot points in the link between EDCs and obesity, including critical windows of susceptibility for
various target tissues, dose-response curves, and potential synergistic effects of mixtures of EDCs and
unhealthy eating patterns.
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